Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare Omnipaque iohexol iodinated contrast media (ICM) for radiologic examinations.
News | Contrast Media
New Report Provides Strategies for Managing Contrast Shortage

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
Decision tree for manual review of currently scheduled contrast-enhanced CT examinations in the event that iodinated contrast supply is critically low. CECT = contrast-enhanced CT. GBCA = gadolinium-based contrast agent. NCCT = non-contrast CT. US = ultrasound.
News | Contrast Media
AJR Publishes Best Practices for Iodinated Contrast Media Shortage

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
Dr. Clifford Cassidy, an Assistant Professor in the University of Ottawa's Faculty of Medicine’s Department of Cellular & Molecular Medicine (CMM) and a scientist at The Royal's Institute of Mental Health Research (IMHR), is the paper’s first author. Image courtesy of the Faculty of Medicine, University of Ottawa
News | Magnetic Resonance Imaging (MRI)
Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media.
News | Contrast Media
Statement from the ACR Committee on Drugs and Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
This action has been taken out of an abundance of caution as a result of potential quality issues identified in its manufacturing processes
News | Nuclear Imaging
Novartis Announces Temporary Halt in Production of Lutathera and Pluvicto

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has received an order from CGN Medical Technologies for a Proteus PLUS[1] proton therapy system to be installed in Yangzhou, China
News | Proton Therapy
IBA Receives Order from CGNNT for a Proteus PLUS System to be Installed in Yangzhou, China

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
New Information Statement Addresses How Labs Should Manage Evolving Issues as Pandemic Shifts Toward Chronic Endemic State
News | Coronavirus (COVID-19)
ASNC, IAEA, SNMMI Update COVID-19 Best Practices for Nuclear Cardiology Labs

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

Time May 04, 2022
arrow
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, announced the enrollment of the first patient into its PREMIER registry, a prospective, real-world evidence clinical outcomes registry for patients with all stages of cancer, at the University of Texas (UT) Southwestern in Dallas.
News | Radiation Therapy
RefleXion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer

May 4, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) ...

Time May 04, 2022
arrow
Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., today announced the release of the SunSCAN 3D cylindrical water scanning system for linear accelerator (linac) commissioning, beam scanning and annual Quality Assurance (QA) in Radiation Therapy.
News | Quality Assurance (QA)
Sun Nuclear Introduces SunSCAN 3D, Next-Generation Cylindrical Water Scanning System

May 3, 2022 — Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., today announced the ...

Time May 03, 2022
arrow
A schematic of the 99Mo/99mTc production system based on an electron linear accelerator and activated carbon-based 99mTc generator
News | Radiopharmaceuticals and Tracers
New Production Method Promises to End Medical Radioisotope Shortages

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

Time April 22, 2022
arrow
Prof. Dr. Samer Ezziddin, image courtesy of Thorsten Mohr/Saarland University
News | Prostate Cancer
New Radiotracer Yields Huge Increase in Accuracy of Localizing Prostate Cancer relapses

April 15, 2022 — Prostate cancer is the most common malignant tumor in men in Germany, with about 62,000 new cases ...

Time April 14, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) released a new online course designed to provide cardiovascular and other nuclear medicine physicians with the knowledge needed to establish a culture of safety and quality in their nuclear imaging laboratories.
News | Nuclear Imaging
New ASNC/SNMMI Training Course Helps Physicians Meet U.S. Requirements for Handling Medical Radioisotopes

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Time April 13, 2022
arrow
Quantitative analysis of pre-treatment PSMA PET/CT in a patient undergoing treatment with ¹⁷⁷Lutetium-PSMA-617/NOX66. Post-treatment PSMA PET/CT demonstrates reduced tumor volume and PSMA intensity. Images created by S Pathmanandavel and L Emmett, St Vincent's Hospital, Sydney, Australia.
News | PET-CT
New Radionuclide Combination Therapy Safe and Effective in Metastatic Prostate Cancer Patients

April 11, 2022 — A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre ...

Time April 11, 2022
arrow
The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease.
News | PET Imaging
CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

April 8, 2022 — The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab ...

Time April 08, 2022
arrow
RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion China has sold together with Mevion’s HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China
News | Treatment Planning
Tongji Hospital Selects RayStation

April 7, 2022 — RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion ...

Time April 07, 2022
arrow
Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).
News | Contrast Media
Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission Tomography (PET) radiopharmaceutical imaging agent which aims to assist in the evaluation of adult patients with suspected Parkinsonian syndromes, support research and improve patient care. 
News | PET Imaging
GE Healthcare Announces First Patient Dosed in Phase III Clinical Trial for New Dopamine Transporter Imaging Radiopharmaceutical

March 29, 2022 — GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission ...

Time March 29, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now